Scaffold proteins form multiprotein complexes that are central to the regulation of intracellular signaling. The scaffold protein ezrin-radixin-moesin-binding phosphoprotein 50 (EBP50) is highly expressed at the plasma membrane of normal biliary epithelial cells and binds epidermal growth factor receptor (EGFR), a tyrosine kinase receptor with oncogenic properties. This study investigated EBP50-EGFR interplay in biliary cancer. We report that in a collection of 106 cholangiocarcinomas, EBP50 was delocalized to the cytoplasm of tumor cells in 66% of the cases. Ectopic expression of EBP50 was correlated with the presence of satellite nodules and with the expression of EGFR, which was at the plasma membrane, implying a loss of interaction with EBP50 in these cases. In vitro, loss of interaction between EBP50 and EGFR was mimicked by EBP50 depletion using a small interfering RNA approach in human biliary carcinoma cells co-expressing the two proteins at their plasma membrane, and in which interaction between EBP50 and EGFR was validated. EBP50 depletion caused an increase in EGFR expression at their surface, and a sustained activation of the receptor and of its downstream effectors (extracellular signal-regulated kinase 1/2, signal transducer and activator of transcription 3) in both basal and EGF-stimulated conditions. Cells lacking EBP50 showed epithelial-to-mesenchymal transition-associated features, including reduction in E-cadherin and cytokeratin-19 expression, induction of S100A4 and of the E-cadherin transcriptional repressor, Slug, and loss of cell polarity. Accordingly, depletion of EBP50 induced the disruption of adherens junctional complexes, the development of lamellipodia structures and the subsequent acquisition of motility properties. All these phenotypic changes were prevented upon inhibition of EGFR tyrosine kinase by gefitinib. These findings indicate that loss of EBP50 at the plasma membrane in tumor cells may contribute to biliary carcinogenesis through EGFR activation.
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Introduction
Scaffold proteins organize functional complexes and modulate kinase activities, thereby contributing to accurate coordination of signaling pathways (Bhattacharyya et al., 2006) . Abnormal expression of scaffold proteins has been linked to different types of cancer in human (Claperon and Therrien, 2007) . Ezrin-radixinmoesin-(ERM)-binding phosphoprotein 50 (EBP50; also named NHERF-1 for Na þ /H þ exchanger regulatory factor-1) is a scaffold protein that is strongly expressed in the liver, and in particular beneath the plasma membrane of biliary epithelial cells (Fouassier et al., 2001 (Fouassier et al., , 2009 . Previous studies have suggested that EBP50 could also form protein complexes at the adherens junctions (AJs), by directly interacting with b-catenin (Shibata et al., 2003; Kreimann et al., 2007) . More recently, there has been increasing evidence for a dual role of EBP50 in cancer, depending on its intracellular localization. Indeed, EBP50 appears to behave as a tumor suppressor when located at the plasma membrane, whereas intracellular EBP50 may have oncogenic effects (Shibata et al., 2003; Georgescu et al., 2008; Hayashi et al., 2010) .
EBP50 possesses two PSD-95/Dlg/Zonula occludens-1 (PDZ) protein-interacting domains and a C-terminal binding domain for ERM proteins that interact with the actin cytoskeleton (Weinman et al., 1993; Reczek et al., 1997) . Through its binding domains, EBP50 exerts anchoring functions at the interface of the plasma membrane and cytoplasm. It binds transmembrane proteins, including the epidermal growth factor receptor (EGFR), a tyrosine kinase receptor implicated in carcinogenesis (Lazar et al., 2004; Takahashi et al., 2006) .
Biliary carcinomas (cholangiocarcinomas) are malignant tumors that arise from the biliary epithelium.
Overexpression and sustained activation of EGFR are associated with tumor progression in biliary carcinoma (Yoon et al., 2004; Yoshikawa et al., 2008) . In different types of cancer, EGFR activation disturbs cell-cell adhesion by destabilizing the E-cadherin/b-catenin complex, promotes epithelial-to-mesenchymal transition (EMT) and contributes to the acquisition of a motile phenotype (Henson and Gibson, 2006; Sebastian et al., 2006) .
Here, we show that disturbance of EBP50 interaction with EGFR, which may occur in human cholangiocarcinoma owing to EBP50 ectopic localization in the cytoplasm, enhances EGFR activation and triggers the acquisition of EMT phenotypic features and migratory properties. These findings indicate that abnormal EBP50 expression may contribute to biliary carcinogenesis through EGFR activation.
Results

Expression of EBP50 in human cholangiocarcinomas
Expression of EBP50 was analyzed in a collection of 106 human intrahepatic cholangiocarcinomas using immunohistochemistry on tissue microarrays. Most of the tumors (87%) expressed EBP50, moderately or strongly in 52% of the cases, and weakly in 35% of the cases. In normal biliary epithelium and in 21% of cholangiocarcinomas, EBP50 was concentrated at the plasma membrane, whereas in 66% of the tumors, EBP50 was delocalized to the cytoplasm (Figures 1a-c) . The statistical analyses of all tumors in the collection showed a significant association between the cytoplasmic expression of EBP50 and the presence of satellite nodules (42% vs 20%, P ¼ 0.018) (Figure 1d ). No correlation was found between EBP50 status and, the differentiation grade, the type of cholangiocarcinoma (peripheral vs hilar), perineural invasion, tumor size, node or vascular invasion.
EGFR expression was detected in 68% of the tumors and, as in normal biliary epithelium, was predominantly located at the plasma membrane (Figures 1e and f) . Statistical analyses showed a significant association between the cytoplasmic delocalization of EBP50 and the expression of EGFR (63% vs 30%, P ¼ 0.002) (Figure 1g ). We suggested that in these cases, EGFR interaction with EBP50 could be defective, owing to ectopic expression of EBP50.
EBP50 silencing increases EGFR expression and downstream signaling in biliary carcinoma cell lines
To model loss of interaction between EBP50 and EGFR, downregulation of EBP50 expression was achieved by small interfering RNA (siRNA) in a biliary carcinoma cell line, Mz-ChA-1, that expressed endogenous EGFR and EBP50 at the plasma membrane ( Figure 2a) . Interaction of the two proteins in these cells was validated by immunoprecipitation ( Figure 2b) . Transfection of the cells with control siRNA did not affect endogenous expression of EBP50 (not shown), whereas transfection with EBP50 siRNA caused a decrease in EBP50 mRNA and protein levels for up to 7 days after transfection (Figures 2c-e) . After EBP50 depletion, EGFR was readily detected at the plasma membrane (Figure 2e ), in keeping with in vivo findings.
Basal and EGF-stimulated activation of EGFR and its downstream effectors was then examined in cells silenced for EBP50 by immunoblotting using phosphospecific and total antibodies. In control cells, EGF caused a transient activation of EGFR (as attested by increased phosphorylation of two different tyrosines) and of extracellular signal-regulated kinase (ERK)1/2 and signal transducer and activator of transcription 3 (STAT3) that culminated at 5 min and progressively returned to the basal level by 120 min (Figure 3a) . In EBP50-silenced cells, the basal activation of EGFR was higher than in controls (Figure 3a, time 0) . In addition, the phosphorylation levels of EGFR, ERK1/2 and STAT3 following stimulation with EGF were all higher and increased for longer in cells silenced for EBP50 than in controls (Figure 3a) .
To confirm the high basal EGFR phosphorylation in EBP50-silenced cells, EGFR immunoprecipitates were obtained from untreated Mz-ChA-1 and TFK-1, another human biliary carcinoma cell line that expresses high level of EBP50 (Figure 3b ), and were analyzed using a phospho-tyrosine antibody. In both cell lines, EBP50 silencing stimulated EGFR phosphorylation in basal conditions (Figure 3c , left and middle panels). Conversely, in HuCCT1, a biliary carcinoma cell line, with low levels of endogenous EBP50 (Figure 3b ), transduced expression of exogenous EBP50 abolished the basal EGFR phosphorylation (Figure 3c , right panel). By contrast, basal and insulin-stimulated insulin receptor tyrosine kinase activities were not affected by the EBP50 status in Mz-ChA-1 cells (Figure 3d ). These findings indicate that loss of EBP50 in biliary carcinoma cells leads to EGFR activation and, consequently, of its downstream signaling pathways.
Biliary epithelial cells express EGFR ligands (Werneburg et al., 2003) . To explore if basal EGFR activation consecutive to EBP50 silencing involved the autocrine production of EGFR ligands, siRNA-transfected cells were treated with GM6001, a metalloprotease inhibitor that blocks the proteolytic cleavage of EGFR proligands in Mz-ChA-1 cells (Finzi et al., 2009) . In control and EBP50-silenced cells, GM6001 markedly decreased basal tyrosine EGFR phosphorylation, implying an autocrine stimulation of EGFR in both conditions (Figure 4a ). To further illustrate that EGFR signaling was overactivated in biliary carcinoma cells depleted of EBP50, we examined the response to gefitinib, a competitive inhibitor of the ATP-binding site of EGFR. Control and EBP50-silenced cells were treated with EGF and a series of gefitinib concentrations. At most concentrations tested, gefitinib inhibition of EGFR phosphorylation was greater in EBP50-silenced cells than in controls (Figure 4b ), consistent with a higher activation status of EGFR in EBP50-depleted cells.
As EBP50 regulates the membrane expression of its binding partners (Hoque and Cole, 2008; Li et al., 2010) , Loss of EBP50-EGFR interplay in biliary carcinoma A Clapéron et al we next determined if EBP50 silencing modified EGFR protein level at the cell surface by flow cytometry analysis of non-permeabilized cells. In basal conditions, EGFR protein was significantly more abundant at the cell surface of EBP50-silenced cells than of controls (Figures 4c and d) . After the addition of EGF, which causes EGFR activation and internalization, the amount of receptor at the cell surface decreased both in controls and EBP50-silenced cells, but remained significantly higher in EBP50-silenced cells than in controls for at least 10 min ( Figure 4d ).
Altogether, these data indicate that cells depleted of EBP50 display more EGFR at the cell surface and this may lead to EGFR activation through an autocrine ligand-dependent mechanism.
EBP50 silencing elicits EMT-associated features through EGFR activation EBP50 acts as a linker between F-actin-binding molecules and cell junctional proteins (for example, b-catenin), and thereby presumably participates in cell adhesion (Curto et al., 2007; Kreimann et al., 2007) . We tested whether this mechanism involves EGFR. In Mz-ChA-1 cells, EBP50 and EGFR were found to be colocalized with E-cadherin ( Figure 2a ) and b-catenin (not shown) at AJs. EBP50 silencing caused internalization of E-cadherin into the cytoplasm (Figure 5a , upper panels), and delocalization of b-catenin into the cytoplasm and the nucleus of the cells (Figure 5a , lower panels and insets). These effects were reversed by gefitinib ( Figure 5a ). The disruption of AJs observed 
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A Clapéron et al was typical of EMT, so other features of this process were explored in EBP50-silenced cells. E-cadherin mRNA and protein were less abundant in these cells than in controls ( Figure 5b , left and middle panels).
In addition, the expression of Slug, a transcription factor that represses E-cadherin gene expression during EMT, was upregulated by approximately threefold in EBP50-silenced cells ( Figure 5b , right panel). The expression of another epithelial marker, cytokeratin 19, was decreased by approximately 50% in EBP50-silenced cells ( Figure 5c , left panel), whereas the expression of the mesenchymal marker S100A4 was increased by approximately twofold ( Figure 5c , right panel). EMT is also characterized by a loss of cell polarity. The polarity of control cells was confirmed by the presence of zonula occludens-1 (ZO-1) at tight junctions. Immunofluorescence analysis revealed the delocalization of ZO-1 to the cytoplasm in EBP50-silenced cells, and this effect was 
A Clapéron et al prevented in the presence of gefitinib (Figure 5d ). Collectively, these findings indicate that the loss of EBP50 from biliary carcinoma cells induces the emergence of EMT-associated phenotypic changes through EGFR activation.
EBP50 silencing promotes cell scattering and motility through EGFR activation Control Mz-ChA-1 cells grew in clusters, whereas cells depleted of EBP50 displayed a fibroblast-like phenotype (Figures 6a and b, arrowhead) . The count of isolated cells as a proportion of total cell number showed that cell scattering was significantly greater by 20% in EBP50-silenced than in control cells (Figure 6d ). Cell dispersion induced by EBP50 silencing was reversed by the EGFR inhibitor, gefitinib (Figures 6c and d) . Consistent with the acquisition of scattering properties, rearrangements of the actin cytoskeleton occurred in EBP50-silenced cells. Indeed, in Mz-ChA-1 control cells, F-actin was concentrated beneath the plasma membrane and at the leading edge of cell clusters. In contrast, a remodeling of actin was observed in EBP50-depleted cells (Figure 7a ). No such rearrangements of the actin cytoskeleton were observed when cells were treated with gefitinib ( Figure 7a) . A fibroblast-like phenotype and cytoskeleton remodeling were also observed in TFK-1 cells depleted for EBP50 (not shown). To assess the presence of cell migratory structures, we used immunofluorescence staining of cortactin, a marker of 
A Clapéron et al lamellipodia. In control cells, no cortactin staining was observed at the leading edge of the cells (Figure 7b ). In EBP50-silenced cells, cortactin was found at the leading edge of the fibroblast-like cells, evidence of lamellipodia formation. This process was inhibited by gefitinib. No formation of filopodia microspikes was visualized by fascin immunostaining in EBP50-depleted cells (not shown). Live-cell imaging was used to compare motile behavior of EBP50-depleted cells and controls. Control Mz-ChA-1 cells moved at an average velocity of 0.05±0.005 mm/min and with a persistence of 0.11 ± 0.01 (n ¼ 17), mainly due to the movement of the entire colony, a phenomenon that is typical of growing epithelial cells. EBP50-silenced cells moved more persistently 0.19 ± 0.01 (Po0.01 vs controls) and 60% faster, at a speed of 0.08 ± 0.004 mm/min (n ¼ 21 cells; Po0.01 vs controls). Representative tracks of five cells in each condition are shown in Figure 7c . Next, we used a transwell filter assay to test the motility of Mz-ChA-1 cells towards medium containing growth factors. The efficiency of cell migration was increased by approximately 50% upon EBP50 depletion (Figure 7d ). The migration activity of EBP50-silenced cells was abolished by gefitinib. These findings suggest that loss of EBP50 from biliary carcinoma cells Figure 4 Loss of EBP50 from biliary carcinoma cells increases EGFR activation through an autocrine loop and EGFR abundance at the cell surface. Mz-ChA-1 cells were transfected with control or EBP50 siRNA (100 nM). (a) SiRNA-transfected cells were incubated with the metalloproteinase inhibitor GM6001 (10 mM) for 24 h. Total EGFR was immunoprecipitated with an anti-EGFR antibody. EGFR phosphorylation was analyzed by western blotting using an anti-phospho-tyrosine antibody. EGFR and EBP50 contents were assessed by western blot. Representative blots of three experiments are shown. Note that exposure time for Figure 4a is five times longer than that for Figure 3c (left panel). (b) SiRNA-transfected cells were pretreated with a series of gefitinib concentrations (0-2 mM) for 24 h and incubated with EGF (100 ng/ml) for 30 min. EGFR activation was evaluated by western blotting using a phospho-specific antibody. EGFR and EBP50 contents were assessed by western blotting. Values for activation were calculated as ratios between phosphorylated forms and total protein levels. 
A Clapéron et al allows the acquisition of migratory properties through EGFR activation.
Discussion
The scaffold protein EBP50 contains several PDZ modules and was initially viewed as a passive linker between transmembrane proteins and the cortical cytoskeleton underlying the plasma membrane. The recent identification of EBP50-binding molecules with catalytic activity, particularly EGFR (Lazar et al., 2004; Takahashi et al., 2006) , suggests that EBP50 is an active important player in regulating biological responses. We report evidence that in vivo, EBP50 and EGFR might interact at the plasma membrane in normal and tumoral biliary epithelium. However, in a majority of biliary tumors, EBP50 expression is ectopic in the cytoplasm of the cells, preventing its interaction 
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A Clapéron et al with EGFR at the plasma membrane. Experiments conducted in vitro demonstrated that loss of EBP50 in biliary carcinoma cell lines that expressed both proteins at the plasma membrane leads to greater activation of EGFR and consequently the acquisition of EMT and cell motility properties. This is the first demonstration that depletion of EBP50 in epithelial cancer cells promotes activation of EGFR and two of its downstream signaling pathways (ERK and STAT3). We show that gefitinib inhibition of EGFR phosphorylation was greater in EBP50-silenced cells than in controls, suggesting that in these cells EGFR-binding site for ATP was more accessible to gefitinib. Scaffold proteins have been shown to promote conformational changes of their binding partners (Dard and Peter, 2006; Cortese et al., 2008) . The fact that in EBP50-silenced cells, EGFR was more accessible, both to its ligand(s) and to gefitinib, supports a scenario in which EBP50 induces masking/unmasking of intramolecular interaction sites by altering EGFR conformation. Moreover, we show that depleting EBP50 in biliary carcinoma cells causes an increase in the amount of EGFR at the cell surface, a phenomenon that may explain the enhanced activation of the receptor in response to secreted EGF ligands. Likewise, depletion of EBP50 increases the amount of the multidrug resistance protein 4 (MRP4) transporter at the plasma membrane of human epithelial cervical cancer cells (Hoque and Cole, 2008) . However, the mechanism by which this occurs remains unknown. In apparent conflict with present results, it was previously reported that in HeLa cells, which display similar levels of endogenous EBP50 as Mz-ChA-1 cells (personal data), EBP50 overexpression induced a sustained activation of EGFR by increasing the level of EGFR at the cell surface (Lazar et al., 2004) . A possible explanation that would reconcile these results with ours is if overexpressed EBP50 exerted dominant-negative effects, a phenomenon well characterized for scaffold proteins (Vondriska et al., 2004) .
We report that depletion of EBP50 triggers disruption of AJs by inducing the internalization of E-cadherin and b-catenin. This effect is due to enhanced activation of EGFR caused by the loss of EBP50-EGFR interaction as an EGFR inhibitor reverses this process. It has already been suggested that EBP50 is functionally involved in cortical stabilization of the E-cadherin/bcatenin complex in epithelial cells (Shibata et al., 2003; Kreimann et al., 2007) . A close relationship between EGFR and AJs stability has also been established previously. Indeed, EGFR activation leads to the phosphorylation of AJ components (including b-catenin), causing the disruption of intercellular contacts (Lee et al., 2010) . Therefore, our findings suggest that EBP50 may contribute to the E-cadherin/b-catenindependent intercellular adhesion by acting directly on EGFR signaling output. Curto et al. (2007) demonstrated that merlin/Nf2 tethers EBP50 to the cell cytoskeleton (Murthy et al., 1998) and thereby participates in the stabilization of AJs through the regulation of EGFR. The observation that EBP50, but not merlin/ Nf2, interacts directly with EGFR (Lazar et al., 2004; Takahashi et al., 2006; Curto et al., 2007) , suggests that EBP50 regulates EGFR signaling per se.
In addition to the disruption of cell-cell contact, EBP50 silencing is associated with features typical of EMT, including nuclear localization of b-catenin, reduced expression of E-cadherin and cytokeratin 19, induced expression of Slug and S100A4, loss of cell polarity and cell migration. Recently, Hayashi et al. (2010) have showed that depletion of EBP50 in colorectal cell lines led to cell motility through induction of EMT program. Our study demonstrates that effects of EBP50 depletion on EMT and cell migration can be mediated by activated EGFR in carcinoma cells, providing for the first time a mechanism by which EBP50 regulates cell EMT phenotypic features. On the basis of present and previous studies, a model depicting the cellular consequences of defective interaction between EBP50 and EGFR at the plasma membrane of cancer cells is proposed in Figure 8 .
We are the first to report alterations of EBP50 subcellular localization and expression in a large series of cholangiocarcinoma samples. EBP50 is present at the plasma membrane in physiological conditions, but often displays ectopic cytoplasmic expression in cholangiocarcinoma tumors. Similar cytoplasmic expression of EBP50 has been described in other human carcinomas, including breast, liver (hepatocellular carcinoma), brain and colon (Stemmer-Rachamimov et al., 2001; Shibata et al., 2003; Cardone et al., 2007; Song et al., 2007; Hayashi et al., 2010; Molina et al., 2010) . In these tumors, we show an association between EBP50 cytoplasmic expression and the presence of EGFR at 
A Clapéron et al the plasma membrane. Therefore, we may postulate that owing to aberrant cytoplasmic localization, the absence of EBP50 from the plasma membrane eliminates its regulatory action on EGFR, which accumulates at the plasma membrane. Our in vitro data support the assertion that the loss of EBP50 at the plasma membrane in human biliary carcinoma leads to increased EGFR activation. In keeping with the model Figure 7 Loss of EBP50 from biliary carcinoma cells enhances cell motility and migration due to EGFR activation. Mz-ChA-1 cells transfected with control or EBP50 siRNA (100 nM) were pretreated or not with gefitinib (1 mM) for 2 h. (a, b) Actin cytoskeleton and lamellipodia structures were analyzed by immunofluorescence using phalloidin (a) and anti-cortactin antibody (b), respectively. Representative images of three experiments are shown. Scale bar, 25 mm (a) and 4 mm (b). (c) SiRNA-transfected cells were analyzed by time-lapse microscopy over 48 h. Tracks of five representative cells for each condition are shown. (d) Cell migration towards a chemoattractant (2.5% serum) was measured by Transwell chamber assay. Data are means ± s.e.m of three experiments performed in triplicate. *Po0.05; NS: not significant.
A Clapéron et al proposed by Georgescu et al. (2008) , these data indicate that the loss of EBP50 or its shift from the plasma membrane to the cytoplasm contributes to relieving its tumor suppressor functions . In agreement with this view, abnormal localization of EBP50 in the cytoplasm of biliary carcinoma was associated with the formation of intrahepatic metastases (satellite nodules). We found no significant association between EBP50 status and the other clinicopathological features. One possible explanation is that the human cholangiocarcinoma specimens included in our study were from patients who underwent surgical resection and, therefore, had better clinical outcome than is often the case (Guedj et al., 2009 ).
In conclusion, we demonstrate that interaction between EBP50 and EGFR is relevant in the biliary epithelium and that loss of this interaction may contribute to biliary cancer progression. We also provide evidence for a novel function for EBP50 as a negative regulator of EGFR that reinforces the tumor suppressor properties of the protein when localized at the plasma membrane in cancer cells.
Materials and methods
Immunohistochemical analysis of human cholangiocarcinomas
Patients' clinicopathological characteristics. We retrospectively retrieved, from the files of surgical and pathology departments, the cases of 106 patients who underwent liver resection for intrahepatic cholangiocarcinoma, between 1995 and 2006 at Beaujon Hospital, Clichy, France. The clinicopathological characteristics of these patients have been reported previously (Guedj et al., 2009 ). In all, 54 patients were men and 52 were women, with a mean age of 59.5 ± 11 years. A total of 59 tumors (56%) were classified as peripheral and 47 (44%) as hilar intrahepatic cholangiocarcinomas. Risk factors for chronic liver disease were noted in 63 patients (59%). Median size of the tumor was 4 cm. All tumors were adenocarcinomas. In total, 55 cases (51%) were well differentiated and 51 were moderately/poorly differentiated (49%) adenocarcinomas. Adenocarcinomas with mucus secretion were observed in 82 patients (77%). Satellite nodules, perineural, vascular and node invasion were present in 31, 62, 33 and 31%, respectively. The patients' survival at 1, 2 and 5 years was 65, 54 and 20%, respectively. Normal liver tissue containing normal bile ducts was obtained from patients who underwent liver surgery for focal benign lesions. Informed consent was obtained in all cases before surgery and the study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the institution's human research committee.
Immunohistochemistry. Paraffin-embedded tissue blocks were used to prepare tissue microarrays, on which staining for EBP50 and EGFR was performed using the primary antibodies listed in Supplementary Table S1 and an automated immunohistochemical stainer (streptavidin-peroxidase protocol; Benchmark, Ventana Medical Systems, Tucson, AZ, USA). All sections were evaluated by the same pathologist (NG) using semiquantitative analysis for each antibody.
EBP50 and EGFR immunostaining was considered positive when the percentage of stained cells was X10%. The intensity of the EBP50 staining was graded as weak, moderate or strong.
Cell culture and treatments
Three human biliary carcinoma cell lines were used: Mz-ChA-1 and TFK-1, derived from extrahepatic biliary tract, were obtained from Dr A Knuth (Zurich University, Zurich, Switzerland) (Knuth et al., 1985) and from the German Figure 8 Model depicting the cellular consequences of defective interaction of EGFR with EBP50 in cancer cells. In cells expressing EBP50 beneath the plasma membrane (left panel), EBP50 interacts with EGFR and with b-catenin through its PDZ1 and PDZ2 domains, respectively (Shibata et al., 2003; Lazar et al., 2004; Takahashi et al., 2006) at AJs (Kreimann et al., 2007) . The association of EBP50 with cell cytoskeleton via the ERM proteins contributes to cortical stabilization of the b-catenin/E-cadherin complex (Curto et al., 2007; Kreimann et al., 2007) . In the absence of EBP50 at the plasma membrane, loss of EBP50-EGFR interaction (right panel) causes an increase of EGFR expression at the cell surface and a sustained activation of the receptor and of its downstream effectors (ERK and STAT3). As a result, EGFR activation triggers the phosphorylation of b-catenin (Lee et al., 2010) (dashed arrow), resulting in the disruption of the AJs with E-cadherin internalization and nuclear translocation of b-catenin. In the nucleus, phosphorylated STAT3 and ERK1/2 as well as nuclear b-catenin induce a transcriptional program involved in EMT (for example, Slug mRNA induction) (Lo et al., 2007; Chen et al., 2009; Lambertini et al., 2010) . Ultimately, this program leads to actin cytoskeleton remodeling as well as cell dispersion and migration.
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Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany), respectively, and HuCCT1, derived from intrahepatic biliary tract, was provided by Dr G Gores (Mayo Clinic, Rochester, MN, USA). Mz-ChA-1 and HuCCT1 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 1 g/l glucose, 10 mmol/l HEPES and 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA). TFK1 was cultured in RPMI 1640 supplemented with 10% fetal bovine serum. Mz-ChA-1 and TFK-1 were transfected with 100 nmol/l of either EBP50 siRNA SMARTPool or NonTargeting siRNA Pool 2 (Dharmacon, Lafayette, CO, USA) using Lipofectamine 2000 (Invitrogen) for 3 or 7 days. HuCCT1 cells were transfected with 4 mg of either pEGFP-C2 or pEGFP-EBP50 (kindly provided by D Garbett and Dr A Bretscher, Cornell University, NY, USA) using the JetPRIME agent (Polyplus Transfection, Illkirch, France). Transfected cells were incubated in serum-free medium for 24 h before starting experiments. In some experiments, the cells were preincubated with 1 mM gefitinib (Tocris, Ellisville, MI, USA).
Real-time RT-PCR
Real-time reverse transcription-polymerase chain reaction (RT-PCR) was performed as described previously (Fouassier et al., 2009) . Briefly, total RNA was extracted from cultured cells and used for reverse transcription with 200 U of Moloney murine leukemia virus reverse transcriptase (Invitrogen) for 1 h at 37 1C. Quantitative real-time PCR was performed with the Platinum SYBRGreen kit (Invitrogen) on a LightCycler 1.5 (Roche Diagnostics, Indianapolis, IN, USA). Sequences of sense and antisense primers used to amplify EBP50, Slug, E-cadherin, cytokeratin 19, S100A4 (200 nmol/l each) and 18S (50 nmol/l each) mRNA are provided in Supplementary Table  S2 . Results are reported relative (2 ÀDDCT ) to the control value.
Immunoprecipitation and immunoblot
Cells were harvested in radioimmunoprecipitation buffer (RIPA) supplemented with 1 mM orthovanadate and a protease inhibitor cocktail (Roche Diagnostics) and subjected to centrifugation for 15 min at 4 1C. For immunoprecipitation, total proteins (o1 mg) were precleared with A/G Plus-agarose beads (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 2 h at 4 1C and incubated with antibodies (4 mg) overnight at 4 1C. New A/G Plus-agarose beads were added and the incubation continued for 2 h. Immunoprecipitated proteins were resuspended in Laemmli buffer, boiled, subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes (Biorad, Hercules, CA, USA). The blots were blocked with Tris-buffered saline, 0.1% Tween-20 containing 5% bovine serum albumin or nonfat dry milk, and incubated with primary antibodies (Supplementary Table S1 ) overnight at 4 1C and with secondary horseradish peroxidase-linked antibody (1:2000; Cell Signaling, Danvers, MA, USA) for 1 h at room temperature. Signals were revealed by chemiluminescence and quantified using a ChemiGenius bioimaging system with the GeneTools software (Syngene, Frederick, MD, USA).
Immunofluorescence Immunofluorescence was performed as described previously (Fouassier et al., 2009) . Briefly, cells were fixed in 4% paraformaldehyde for 15 min, permeabilized in 0.1% SurfactAmps X100 (Thermo Scientific, Rockford, IL, USA) for 10 min and blocked with 1% albumin and 10% goat serum for 1 h at room temperature. The cells were incubated overnight with the appropriate antibodies (Supplementary Table S1 ) and then for 1 h at room temperature with secondary fluorescent antibodies (Invitrogen). Finally, to label nuclei, cells were counterstained with TOPRO iodide (Invitrogen) for 10 min during the final wash before mounting (Fluoromount; EMS, Hatfield, PA, USA). Cells were observed with an epifluorescence or an SP2 confocal microscope (Leica, Bannockburn, IL, USA). The scaling range was adjusted manually allowing identical settings for each image.
Flow cytometry
Cultured cells were isolated and re-suspended in 1% paraformaldehyde for 15 min. The cells were incubated in 1% albumin for 10 min and then in 0.3 mg/ml of an antibody raised against the extracellular domain of EGFR (Supplementary Table S1 ) for 1 h. Subsequently, cells were incubated for 1 h with 0.5 mg/ml anti-mouse Alexa-488 antibody, and the level of fluorescence was measured using LSRII flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA).
Scattering assay
Cells were observed by phase microscopy using a Leica microscope. Cell scattering was quantified counting cells detached from colonies vs the total number of cells in random images as described in Masuda et al. (2005) .
Time-lapse microscopy
At 24 h after co-transfection with either control or EBP50 siRNA and with siGLO RISC Free control siRNA, labeled with FITC (Dharmacon), cells were plated onto 35 mm glass bottom dishes (Iwaki-Glass, Chiba, Japan). Images were collected with a CoolSnap HQ camera (Photometrics, Tucson, AZ, USA) mounted on a Nikon (Kingston, UK) Eclipse Ti wide-field microscope stand equipped with Perfect Focus. MetaMorph (Molecular Devices, Sunnyvale, CA, USA) was used to measure cell velocity after capturing live-image time series at Â 20. During the entire experiment, cells were kept at 37 1C under 5% CO 2 . For motility studies, cells were imaged approximately every 15 min for 48 h, and their trajectories were traced using the center of the nucleus as a reference point. Persistence, defined as the absolute distance from the point of origin, was measured.
Transwell migration assay
Cell migration was measured using the QCM 24-well Colorimetric Cell Migration assay (8-mm pore size; BD Biosciences). SiRNA-transfected cells were loaded into the upper chamber of the insert placed in serum-free medium for 24 h, and serum (2.5%) was added to the lower chamber. After 24 h, cells located in the lower chamber were fixed and stained with crystal violet. Optical densities were measured in a microplate reader at 560 nm.
Statistics
For human tumor samples, qualitative variables were analyzed using the two-sided Fisher's exact test. Quantitative data were compared using the non-parametric Mann-Whitney test. The Kolmogorov-Smirnov test (D-value) was used to assess the probability that two flow cytometry histograms were different when D>0.2. Analysis was performed using the IBM SPSS Statistics 17.0 or Expo32 software (Beckman-Coulter, Brea, CA, USA).
